Ken Griffin Theratechnologies Inc. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.78 - $1.01 $5,676 - $7,349	7,277 Added 26.53%	34,704 $29,000
Q1 2023 May 15, 2023	BUY	$0.72 - $1.12 $19,747 - $30,718	27,427 New	27,427 $22,000
Q3 2022 Nov 14, 2022	SELL	$1.98 - $2.42 $20,722 - $25,327	-10,466 Reduced 26.09%	29,646 $70,000
Q2 2022 Aug 15, 2022	BUY	$2.21 - $2.7 $57,360 - $70,078	25,955 Added 183.34%	40,112 $91,000
Q1 2022 May 16, 2022	SELL	$2.37 - $3.24 $17,699 - $24,196	-7,468 Reduced 34.53%	14,157 $35,000

Q3 2021 Nov 15, 2021	BUY	$3.28 - $4.07 $23,392 - $29,027	7,132 Added 49.21%	21,625 $81,000
Q1 2021 May 17, 2021	BUY	$2.2 - $3.94 $31,884 - $57,102	14,493 New	14,493 $56,000
Q2 2020 Aug 14, 2020	SELL	$1.58 - $2.86 $20,224 - $36,608	-12,800 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.43 - $3.23 $43,353 - $97,923	-30,317 Reduced 70.31%	12,800 $21,000
Q4 2019 Feb 14, 2020	BUY	$2.74 - $4.2 $118,140 - $181,091	43,117 New	43,117 $142,000

29.2K

Ticker THTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,141,600
Market Cap $135M
Description
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with l...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.